BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 34884543)

  • 1. The Role of the Immune System in IBD-Associated Colorectal Cancer: From Pro to Anti-Tumorigenic Mechanisms.
    Frigerio S; Lartey DA; D'Haens GR; Grootjans J
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Inflammation in the Development of Colorectal Cancer.
    Muthusami S; Ramachandran IK; Babu KN; Krishnamoorthy S; Guruswamy A; Queimado L; Chaudhuri G; Ramachandran I
    Endocr Metab Immune Disord Drug Targets; 2021; 21(1):77-90. PubMed ID: 32901590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammatory Bowel Disease-Associated Colorectal Cancer: Translational Risks from Mechanisms to Medicines.
    Porter RJ; Arends MJ; Churchhouse AMD; Din S
    J Crohns Colitis; 2021 Dec; 15(12):2131-2141. PubMed ID: 34111282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative analysis of single-cell transcriptome reveals heterogeneity and commonality in the immune microenvironment of colorectal cancer and inflammatory bowel disease.
    Lv H; Mu Y; Zhang C; Zhao M; Jiang P; Xiao S; Sun H; Wu N; Sun D; Jin Y
    Front Immunol; 2024; 15():1356075. PubMed ID: 38529274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammation and colorectal cancer.
    Kraus S; Arber N
    Curr Opin Pharmacol; 2009 Aug; 9(4):405-10. PubMed ID: 19589728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Mitochondria Dysfunction in Inflammatory Bowel Diseases and Colorectal Cancer.
    Kłos P; Dabravolski SA
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NLRP3 Inhibitors as Potential Therapeutic Agents for Treatment of Inflammatory Bowel Disease.
    Perera AP; Kunde D; Eri R
    Curr Pharm Des; 2017; 23(16):2321-2327. PubMed ID: 28155620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis.
    Kim ER; Chang DK
    World J Gastroenterol; 2014 Aug; 20(29):9872-81. PubMed ID: 25110418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morphological, immunohistochemical and molecular features of inflammatory bowel disease associated colorectal carcinoma and associated mucosal lesions - Single institution experience.
    Kamarádová K; Vošmiková H; Rozkošová K; Ryška A; Tachecí I; Laco J
    Pathol Res Pract; 2019 Apr; 215(4):730-737. PubMed ID: 30679085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk?
    Dyson JK; Rutter MD
    World J Gastroenterol; 2012 Aug; 18(29):3839-48. PubMed ID: 22876036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune System, Microbiota, and Microbial Metabolites: The Unresolved Triad in Colorectal Cancer Microenvironment.
    Hanus M; Parada-Venegas D; Landskron G; Wielandt AM; Hurtado C; Alvarez K; Hermoso MA; López-Köstner F; De la Fuente M
    Front Immunol; 2021; 12():612826. PubMed ID: 33841394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dysplasia and colorectal cancer in inflammatory bowel disease: a result of inflammation or an intrinsic risk?
    Breynaert C; Vermeire S; Rutgeerts P; Van Assche G
    Acta Gastroenterol Belg; 2008; 71(4):367-72. PubMed ID: 19317276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intestinal immunomodulation. Role of regulative peptides and promising pharmacological activities.
    Motilva V; Talero E; Calvo JR; Villegas I; Alarcón-de-la-Lastra C; Sánchez-Fidalgo S
    Curr Pharm Des; 2008; 14(1):71-95. PubMed ID: 18220820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of cancer in IBD - a balancing act.
    Mill J; Lawrance IC
    Minerva Gastroenterol Dietol; 2013 Sep; 59(3):261-72. PubMed ID: 23867946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of MicroRNAs in Inflammation-Associated Colorectal Cancer: A Mechanistic Approach.
    Muthusami S; Ramachandran I; Krishnamoorthy S; Sambandam Y; Ramalingam S; Queimado L; Chaudhuri G; Ramachandran IK
    Endocr Metab Immune Disord Drug Targets; 2021; 21(1):67-76. PubMed ID: 32940190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The struggle within: microbial influences on colorectal cancer.
    Arthur JC; Jobin C
    Inflamm Bowel Dis; 2011 Jan; 17(1):396-409. PubMed ID: 20848537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment.
    Axelrad JE; Lichtiger S; Yajnik V
    World J Gastroenterol; 2016 May; 22(20):4794-801. PubMed ID: 27239106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease.
    Brackmann S; Andersen SN; Aamodt G; Langmark F; Clausen OP; Aadland E; Fausa O; Rydning A; Vatn MH
    Scand J Gastroenterol; 2009; 44(1):46-55. PubMed ID: 18609187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malignancies in Inflammatory Bowel Disease.
    Greuter T; Vavricka S; König AO; Beaugerie L; Scharl M;
    Digestion; 2020; 101 Suppl 1():136-145. PubMed ID: 32799195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Cyclophilins in Inflammatory Bowel Disease and Colorectal Cancer.
    Liang L; Lin R; Xie Y; Lin H; Shao F; Rui W; Chen H
    Int J Biol Sci; 2021; 17(10):2548-2560. PubMed ID: 34326693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.